De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study

Canagliflozin is a sodium-glucose co-transporter 2 inhibitor that reduces glycemia as well as the risk of cardiovascular events. Our main objective was to analyze antidiabetic treatment de-intensification and the glycemic efficacy of replacing antidiabetic agents (excluding metformin) with canaglifl...

Full description

Bibliographic Details
Main Authors: Luis M. Pérez-Belmonte, Michele Ricci, Jaime Sanz-Cánovas, Lidia Cobos-Palacios, María D. López-Carmona, M. Isabel Ruiz-Moreno, Mercedes Millán-Gómez, M. Rosa Bernal-López, Sergio Jansen-Chaparro, Ricardo Gómez-Huelgas
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Journal of Clinical Medicine
Subjects:
de-intensification
efficacy
canagliflozin
heart failure
type 2 diabetes
Online Access:https://www.mdpi.com/2077-0383/10/9/2013

Internet

https://www.mdpi.com/2077-0383/10/9/2013

Similar Items